JP2015501833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501833A5 JP2015501833A5 JP2014546692A JP2014546692A JP2015501833A5 JP 2015501833 A5 JP2015501833 A5 JP 2015501833A5 JP 2014546692 A JP2014546692 A JP 2014546692A JP 2014546692 A JP2014546692 A JP 2014546692A JP 2015501833 A5 JP2015501833 A5 JP 2015501833A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- VHPXWPAGHGHDCK-UHFFFAOYSA-N 5-chloro-4-[(3,4-dichlorophenoxy)methyl]-2-fluoro-n-methylsulfonylbenzamide Chemical compound C1=C(F)C(C(=O)NS(=O)(=O)C)=CC(Cl)=C1COC1=CC=C(Cl)C(Cl)=C1 VHPXWPAGHGHDCK-UHFFFAOYSA-N 0.000 claims 3
- 229940124777 Nav1.7 inhibitor Drugs 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576005P | 2011-12-15 | 2011-12-15 | |
| US61/576,005 | 2011-12-15 | ||
| PCT/IB2012/057035 WO2013088315A1 (en) | 2011-12-15 | 2012-12-06 | Sulfonamide derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501833A JP2015501833A (ja) | 2015-01-19 |
| JP2015501833A5 true JP2015501833A5 (OSRAM) | 2016-01-21 |
| JP6058023B2 JP6058023B2 (ja) | 2017-01-11 |
Family
ID=47557422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546692A Expired - Fee Related JP6058023B2 (ja) | 2011-12-15 | 2012-12-06 | スルホンアミド誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9085517B2 (OSRAM) |
| EP (1) | EP2791108B1 (OSRAM) |
| JP (1) | JP6058023B2 (OSRAM) |
| CA (1) | CA2857603C (OSRAM) |
| ES (1) | ES2593533T3 (OSRAM) |
| WO (1) | WO2013088315A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9630929B2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| JP6067031B2 (ja) * | 2012-01-04 | 2017-01-25 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | Ｎ−アミノスルホニルベンズアミド |
| KR101719893B1 (ko) | 2012-05-22 | 2017-03-24 | 제넨테크, 인크. | Ｎ-치환된 벤즈아미드 및 통증의 치료에서 이들의 용도 |
| JP6309519B2 (ja) * | 2012-07-06 | 2018-04-11 | ジェネンテック， インコーポレイテッド | Ｎ置換ベンズアミド及びその使用方法 |
| WO2014153037A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Substituted triazolopyridines and methods of use thereof |
| EP2970156B1 (en) | 2013-03-15 | 2018-07-25 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| AU2014356967A1 (en) * | 2013-11-27 | 2016-07-07 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| MA42118A (fr) | 2015-05-22 | 2018-03-28 | Genentech Inc | Benzamides substitués et leurs méthodes d'utilisation |
| WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| MX386501B (es) | 2015-09-28 | 2025-03-19 | Genentech Inc | Compuestos terapeuticos y sus metodos de uso |
| AU2016351526B2 (en) | 2015-11-13 | 2019-02-21 | In Therapeutics | Sodium channel blocker |
| EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| US10766858B2 (en) | 2016-03-30 | 2020-09-08 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2019532077A (ja) | 2016-10-17 | 2019-11-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| TW201920107A (zh) | 2017-08-31 | 2019-06-01 | 日商拉夸里亞創藥股份有限公司 | 作為ttx-s阻斷劑之雙芳氧基衍生物 |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| PT3762368T (pt) | 2018-03-08 | 2022-05-06 | Incyte Corp | Compostos de aminopirazina diol como inibidores de pi3k-y |
| EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| JP2022515630A (ja) * | 2018-12-26 | 2022-02-21 | ラクオリア創薬株式会社 | Ｎａｖ１．７およびＮａｖ１．８遮断薬としての複素環誘導体 |
| JPWO2021132577A1 (OSRAM) * | 2019-12-27 | 2021-07-01 | ||
| CN113200956B (zh) * | 2021-05-18 | 2022-04-22 | 潍坊医学院 | 一种磺胺苯甲酰胺类衍生物及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| JPH05289262A (ja) | 1992-04-10 | 1993-11-05 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| ATE189217T1 (de) | 1993-03-19 | 2000-02-15 | Merck & Co Inc | Phenoxyphenylessigsäurederivate |
| CA2195758A1 (en) | 1994-08-08 | 1996-02-22 | Scott W. Bagley | Phenoxyphenylacetic acid derivatives |
| AU3642795A (en) | 1994-09-27 | 1996-04-19 | Merck & Co., Inc. | Endothelin receptor antagonists for the treatment of emesis |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| AU2002240235B2 (en) | 2001-01-30 | 2006-07-06 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| TW200524888A (en) | 2003-08-08 | 2005-08-01 | Vertex Pharma | Compositions useful as inhibitors of voltage-gated ion channels |
| JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| DK2076508T3 (da) | 2006-10-18 | 2011-02-21 | Pfizer Prod Inc | Biaryl-ether-urinstof-forbindelser |
| CA2681572C (en) * | 2007-03-23 | 2014-02-11 | Icagen, Inc. | Inhibitors of ion channels |
| KR20100007956A (ko) | 2007-05-03 | 2010-01-22 | 화이자 리미티드 | 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체 |
| US8124610B2 (en) | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
| GB0725214D0 (en) | 2007-12-24 | 2008-02-06 | Karobio Ab | Pharmaceutical compounds |
| WO2009140342A1 (en) | 2008-05-16 | 2009-11-19 | Schering Corporation | Glucagon receptor antagonists, compositions, and methods for their use |
| MX2012003560A (es) * | 2009-09-25 | 2012-10-05 | Astellas Pharma Inc | Compuesto de amida sustituida. |
| JP5289262B2 (ja) | 2009-09-30 | 2013-09-11 | 京セラドキュメントソリューションズ株式会社 | シート搬送装置とこれを備えた画像読取装置及び画像形成装置 |
| WO2011070592A2 (en) | 2009-12-09 | 2011-06-16 | Panacea Biotec Ltd. | Novel sugar derivatives |
| BR112012020271A2 (pt) | 2010-02-11 | 2017-08-29 | Univ Vanderbilt | Benzisoxazóis e azabenzisoxazóis como potencializadores alostéricos de mglur4 composições e métodos de tratamentos de disfunção neurológica |
| CN102892288B (zh) | 2010-02-11 | 2016-02-24 | 范德比尔特大学 | 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法 |
| EP2563794A4 (en) | 2010-04-16 | 2013-12-04 | Methylgene Inc | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY AND ITS USE FOR THE TREATMENT OF EYE DISEASES |
| JP2013532185A (ja) * | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| ES2526981T3 (es) | 2010-07-12 | 2015-01-19 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje |
| JP6309519B2 (ja) * | 2012-07-06 | 2018-04-11 | ジェネンテック， インコーポレイテッド | Ｎ置換ベンズアミド及びその使用方法 |
-
2012
- 2012-12-06 US US14/358,494 patent/US9085517B2/en not_active Expired - Fee Related
- 2012-12-06 EP EP12813989.6A patent/EP2791108B1/en not_active Not-in-force
- 2012-12-06 WO PCT/IB2012/057035 patent/WO2013088315A1/en not_active Ceased
- 2012-12-06 JP JP2014546692A patent/JP6058023B2/ja not_active Expired - Fee Related
- 2012-12-06 ES ES12813989.6T patent/ES2593533T3/es active Active
- 2012-12-06 CA CA2857603A patent/CA2857603C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501833A5 (OSRAM) | ||
| JP2015504067A5 (OSRAM) | ||
| JP2013531031A5 (OSRAM) | ||
| JP2016530259A5 (OSRAM) | ||
| RU2015120216A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2013510120A5 (OSRAM) | ||
| JP2016517417A5 (OSRAM) | ||
| JP2014511891A5 (OSRAM) | ||
| JP2016526540A5 (OSRAM) | ||
| JP2017508789A5 (OSRAM) | ||
| JP2015533177A5 (OSRAM) | ||
| JP2013510124A5 (OSRAM) | ||
| JP2016506962A5 (OSRAM) | ||
| JP2013531029A5 (OSRAM) | ||
| JP2014500295A5 (OSRAM) | ||
| JP2016503797A5 (OSRAM) | ||
| JP2014518882A5 (OSRAM) | ||
| JP2014521688A5 (OSRAM) | ||
| RU2018106453A (ru) | Соединения | |
| JP2015535277A5 (OSRAM) | ||
| JP2016515561A5 (OSRAM) | ||
| JP2016040288A5 (OSRAM) | ||
| JP2013537203A5 (OSRAM) | ||
| RU2013142448A (ru) | Новые сульфонаминохинолиновые антагонисты гепсидина | |
| JP2013544860A5 (OSRAM) |